Pultrusion
Improves fibre impregnation Improves product quality Allows use of fast set resins Reduces fumes in the workplace Reduces clean up time
Pultrusion is a continuous manufacturing technique for the production of fibre reinforced composite materials of predefined dimensions. However there are some problems with the method that limit its use. These can be overcome by using new technology developed at the University. This new method ensures that fibres are spread within the bundle in the optimal way to maximise resin impregnation and ensure voids are not produced in the section. Fibre spreading is carried out in a controlled manner to maximise the degree of filament spreading and minimise the fracture of the filaments. The fibres are then impregnated by a specially designed dispensing system the mixes the resin components using precision gear pumps and a static mixer. This allows the use of fast-curing resin systems, that cannot be used in conventional batch mixed resin baths. These improvements will allow faster production rates and reduced energy usage. By mixing resin on demand it is easier to control environmental solvent levels, improve the air quality for workers and reduce odours in the vicinity of the plant. There are also additional environmental benefits, clean down is easier at the end of the work as there is no resin bath to empty and clean and there is less waste resin to dispose of.
Patent Number: US6441027B1
Application Number: US1999313528A
Inventor: D'Amato, Robert J. | Demore, Nancy Klauber
Priority Date: 2 Aug 1996
Priority Number: US6441027B1
Application Date: 17 May 1999
Publication Date: 27 Aug 2002
IPC Current: A61K004500 | A61K0031335 | A61K0031336 | A61P001518
US Class: 514450
Assignee Applicant: Children's Medical Center Corporation,Boston
Title: Method of regulating the female reproductive system through angiogenesis inhibitors
Usefulness: Method of regulating the female reproductive system through angiogenesis inhibitors
Summary: USE The angiogenesis inhibitor is capable of preventing conception, terminating pregnancy, or treating endometriosis, adenomyosis, dysfunctional uterine bleeding, ovarian cysts, choriocarcinoma or ectopic pregnancy.Administration is, e.g., oral, rectal, vaginal, transdermal, topical or parenteral.
Novelty: Regulation of fertility or treatment of reproductive system disorders by administration of angiogenesis inhibitor, especially O-chloroacetyl carbamoyl fumagillol
化工/材料
化工/材料应用
美国
